Prezcobix (Darunavir/Cobicistat) Patent Expiration, LOE Window & CMS Spending

Prezcobix (Darunavir/Cobicistat) by Johnson & Johnson: FDA Orange Book core substance LOE 2029-09-03 (last listed 2032-10-06), 0 AB generics, $353.1M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN205395 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2029-09-03
Last Listed Patent or Exclusivity Date2032-10-06
Orange Book Patents (*PED Extensions)4 patents (1 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$353.1M
2024 Medicare Part D Spend$255.4M
2024 Medicaid Spend$97.7M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 18.7% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.